A mitochondria-targeting self-assembled carrier-free lonidamine nanodrug for redox-activated drug release to enhance cancer chemotherapy
Ting Yang, Xianfen Zhang, Xing Yang, Ying Li, Jingjing Xiang, Chunbai Xiang, Zhongke Liu, Luo Hai, Saipeng Huang, Lihua Zhou, Ruijing Liang, Ping Gong
Abstract
and pro-apoptotic Bax, and downregulate anti-apoptotic Bcl-2. Generally, Cy-TK-LND NPs exhibit efficient mitochondria-targeted delivery to improve the medicinal availability of LND. Accordingly, such a carrier-free prodrug-based nanomedicine holds promise as an effective cancer chemotherapy strategy.
Topics & Concepts
MitochondrionApoptosisCancer researchCancer cellDownregulation and upregulationCell biologyProdrugChemistryPharmacologyBiologyBiochemistryCancerGeneticsGeneNanoplatforms for cancer theranosticsAdvanced Nanomaterials in CatalysisAdvanced biosensing and bioanalysis techniques